Host: |
HEK293 |
Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human CLEC2D-N-hFc-Avi protein was developed from hek293 and has a target region of N-hFc-Avi. For use in research applications. |
Conjugation: |
Biotin |
Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
Dilution Range: |
Upon receipt centrifuge vial to ensure maximal product extraction, recommended: 20sec, 5K RPM |
Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. |
Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). |
Gene Symbol: |
CLEC2D |
Gene ID: |
29121 |
Uniprot ID: |
CLC2D_HUMAN |
Immunogen Region: |
Arg60-Val191 |
Immunogen: |
DNA sequence encoding Human CLEC2D including a N-hFc-Avi tag was expressed in HEK293 Cells. The recombinant protein was then biotinylated site specific using the AVItag biotinylation technology. |
Post Translational Modifications | N-glycosylated. |
Function | Receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis. Inhibits osteoclast formation. Inhibits bone resorption. Modulates the release of interferon-gamma. Binds high molecular weight sulfated glycosaminoglycans. |
Protein Name | C-Type Lectin Domain Family 2 Member DLectin-Like Nk Cell ReceptorLectin-Like Transcript 1Llt-1Osteoclast Inhibitory Lectin |
Database Links | Reactome: R-HSA-198933 |
Cellular Localisation | Cell MembraneSingle-Pass Type Ii Membrane ProteinIsoform 2: Endoplasmic ReticulumIsoform 4: Endoplasmic Reticulum |
Alternative Protein Names | C-Type Lectin Domain Family 2 Member D proteinLectin-Like Nk Cell Receptor proteinLectin-Like Transcript 1 proteinLlt-1 proteinOsteoclast Inhibitory Lectin proteinCLEC2D proteinCLAX proteinLLT1 proteinOCIL protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance